Allogene CAR-T plant on track despite ‘minor delays’ due to COVID-19 10-Aug-2020 By Nick Taylor Allogene Therapeutics maintains 2021 completion date for US CAR-T manufacturing facility despite COVID-19 causing “minor delays.”
Allogene allies with Notch to make CAR-T production more scalable 13-Nov-2019 By Nick Taylor Allogene Therapeutics forms alliance with Notch Therapeutics to access technology for large-scale production of CAR-T therapies.
Allogene partners with Stanford for allogeneic CAR T production 25-Sep-2019 By Ben Hargreaves Allogene will explore using mRNA technology for the development of allogeneic CAR-T therapies for the treatment of cancer.
Vida generates $600m, triples assets to expand life sciences platform 08-Aug-2019 By Vassia Barba Vida announced the closure of its second fund, which generated $600m to be invested in the further expansion of its life sciences platform.
Cellectis to build CAR-T manufacturing sites in US and Europe 14-Mar-2019 By Ben Hargreaves In a step towards the commercialisation of its ‘off-the-shelf’ CAR-T therapies, Cellectis begins construction of a facility in France and enters lease agreement for US facility.
Allogene builds allogeneic CAR-T site, looking ahead to ‘commercial product’ 27-Feb-2019 By Ben Hargreaves Allogene enters a lease agreement to develop a 118,000-square-foot site for the manufacture of allogeneic CAR-T therapies.